Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002348497 | SCV002642631 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2018-09-25 | criteria provided, single submitter | clinical testing | The c.5277+2T>G intronic variant results from a T to G substitution two nucleotides after coding exon 18 in the BRCA1 gene. This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site; however, direct evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. |
Revvity Omics, |
RCV003132218 | SCV003809757 | pathogenic | not provided | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005093389 | SCV005746075 | pathogenic | Hereditary breast ovarian cancer syndrome | 2025-01-15 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 19 of the BRCA1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 865231). Studies have shown that disruption of this splice site results in activation of a cryptic splice site in intron 19 or skipping of exon 19 (also known as exon 20), and produces a non-functional protein and/or introduces a premature termination codon (PMID: 24667779; internal data). For these reasons, this variant has been classified as Pathogenic. |
Brotman Baty Institute, |
RCV001072611 | SCV001238026 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |